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Abstract
Background: Exhaled nitric oxide (FENO) measurements are used as a surrogate marker for
eosinophilic airway inflammation. However, many constitutional and environmental factors affect
FENO, making it difficult to devise reference values. Our aim was to evaluate the relative
importance of factors affecting FENO in a well characterised adult population.
Methods: Data were obtained from 895 members of the Dunedin Multidisciplinary Health and
Development Study at age 32. The effects of sex, height, weight, lung function indices, smoking,
atopy, asthma and rhinitis on FENO were explored by unadjusted and adjusted linear regression
analyses.
Results: The effect of sex on FENO was both statistically and clinically significant, with FENO levels
approximately 25% less in females. Overall, current smoking reduced FENO up to 50%, but this
effect occurred predominantly in those who smoked on the day of the FENO measurement. Atopy
increased FENO by 60%. The sex-related differences in FENO remained significant (p < 0.001) after
controlling for all other significant factors affecting FENO.
Conclusion: Even after adjustment, FENO values are significantly different in males and females.
The derivation of reference values and the interpretation of FENO in the clinical setting should be
stratified by sex. Other common factors such as current smoking and atopy also require to be
taken into account.
Background
Measurement of exhaled nitric oxide (FENO) is increas-
ingly recognised as an important addition to pulmonary
function testing in clinical practice [1]. FENO may be used
as a surrogate marker for airway eosinophilia [2], and as
an alternative to other more invasive or time-consuming
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assessments of airway pathology such as induced sputum,
[2,3] bronchial lavage fluid, [4] or mucosal biopsy. [5-7]
Against this background, FENO measurements are increas-
ingly being used to clarify the aetiology of non-specific
respiratory symptoms as well as monitor levels of inflam-
mation in conditions characterised by airway eosi-
nophilia [8].
There are a number of demographic and biological factors
which cause variation in FENO levels. The commonest are
cigarette smoking [9,10] and atopy [11-13] with or with-
out allergic rhinitis. [13,14] Others include age [15,16],
and IgE levels [17]. However, conflicting results concern-
ing the importance of these factors has precluded a clear
definition of so-called "normal" values. Buchvald et al.
have reported reference values in a large population of
children, but important biological confounders were eval-
uated only by questionnaire. [15] The same issues were
addressed more recently in adults by Olin et al. [18] and
Travers et al. [19], and Travers et al. provided reference
ranges which sought to take account of commonly
encountered variables which affect FENO. However, there
are some significant inconsistencies between these
reports, not least in respect of the effects of sex on FENO.
Clearly further data are needed so that routine FENO
measurements can be interpreted appropriately. In the
present study, comprising a well characterised cohort of
nearly 1000 32-year old individuals born in Dunedin,
New Zealand, we obtained detailed clinical and labora-
tory information regarding factors affecting FENO, and
their potential relevance to reference ranges for FENO was
evaluated.
Methods
The Dunedin Multidisciplinary Health and Development
Study is a cohort study of 1037 children (52% male) born
between April 1972 and March 1973. [20,21] Follow-up
assessments have been conducted at ages 3, 5, 7, 9, 11, 13,
15, 18, 21, 26, and at 32 years, at which time 972 (96%)
of 1015 living Study members participated.
At age 32, Study members were questioned about current
and previous asthma, as well as symptoms of wheezing,
cough, episodic shortness of breath, hay fever and rhinitis.
Current asthma was defined as reported diagnosed
asthma with symptoms in the last 12 months. Current
wheezing was recorded as any wheeze in the last 12
months but excluding subjects with only one or two epi-
sodes each lasting less than 1 hour. Asthma treatment was
any inhaled bronchodilator, corticosteroid or cromogly-
cate medication. Current smoking was defined as smok-
ing tobacco cigarettes daily for at least one month during
the previous 12 months, or smoking cannabis 6 or more
times during the previous 12 months. Current smokers
were further subdivided into two groups: those who did
and did not smoke on the study day. Ex-smokers were
defined as having discontinued for at least 12 months.
Height and weight in light clothing without shoes were
measured to calculate body mass index (BMI) in kg/m2.
FENO was then measured on-line using a Logan LR 2000
series chemiluminescence analyser (Logan Research Ltd.,
Rochester, England) in accordance with ATS/ERS guide-
lines at a flow rate of 50 mL/sec. [22] Exhaled nitric oxide
in parts per billion (ppb) was recorded continuously
throughout expiration. Individual results were read at the
first nitric oxide plateau and the mean of two acceptable
tests was recorded. A third was obtained only where one
or both of the first two were considered to be technically
unsatisfactory. The NO recording was determined for each
test by two observers on a separate occasion. The first 44
Study members were tested using a flow rate of 250 mL/
second and results were adjusted to 50 mL/second using a
previously validated formula [23].
FENO measurements were obtained immediately prior to
carrying out spirometry. Skin prick testing included house
dust mite (D. pteronyssinus), grass, cat, dog, horse, cock-
roach, wool, Aspergillus fumigatus, alternaria, penicillium,
and cladosporium. A weal diameter 3 mm or greater than
the saline control was considered positive. Atopy was
defined as a positive response to one or more allergens. A
blood sample was obtained for eosinophil count and total
serum immunoglobulin E (IgE).
Statistical analysis
Study members who were pregnant at the time of assess-
ment (n = 31) were excluded from all analyses. FENO
measurements were not normally distributed, and were
log transformed prior to analysis. Both univariate and
multivariate linear regression analyses were performed to
identify those factors which significantly affected FENO
levels and to derive regression equations, with stratifica-
tion for those factors which were shown to significantly
affect exhaled nitric oxide levels. The selection of appro-
priate linear regression models was based on maximum R-
square and an examination of the residuals, to ensure an
adequate model fit. Significant interaction terms (p <
0.05) were retained in the model. Results are presented as
anti-log values with 95% confidence intervals following
back-transformation.
Ethics
The Otago Ethics Committee approved the study and writ-
ten informed consent was obtained.
Results
Eight hundred and ninety-five Study members completed
the respiratory procedures in the Study. Of these, 471
(52.6%) were male, 486 (54.8%) were atopic, 349Respiratory Research 2007, 8:82 http://respiratory-research.com/content/8/1/82
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(39.0%) had rhinitis/hay fever, 253 (28.3%) had current
wheeze, 156 (17.4%) had current asthma, and 54 (6.6%)
were using inhaled corticosteroid treatment. Three hun-
dred and ninety five were current smokers (44.1%), of
whom 235 (59.5%) smoked on the study assessment day
prior to testing, and 107 were ex-smokers (12.0%). Two
hundred and fifteen were cannabis smokers (24%), of
whom 78 (8.7%) smoked cannabis alone.
The FENO values obtained from the Study population are
shown in Table 1. Data relating to smoking status are
shown in Table 2. FENO was on average 25% higher in
males than females (males: 15.3 ppb [95%
C.I.:14.3–16.3] versus females: 11.6 ppb [95% C.I.:
11.0–12.4]; p < 0.0001; Table 1). Unadjusted analyses
revealed that, for all Study members, there were also sig-
nificant differences in FENO in relation to height, FEV1,
FEV1 % predicted and FVC (Table 3). However, none of
Table 1: Mean values (with 95% confidence intervals) for FENO stratified by sex, smoking, atopy, rhinitis current wheeze and asthma. * 
not all Study members underwent skin testing
All All subjects, n = 895
13.4 (12.9, 14.1)
Gender Male, n = 471
15.3 (14.3,16.3)
Female, n = 424
11.6 (11.0, 12.4)
Smoking Current smoker 
(smoked on the day of 
testing)
Current smoker (not 
smoked on the day of 
testing)
Ex-smoker or non-
smoker
Current smoker 
(smoked on the day of 
testing)
Current smoker (not 
smoked on the day of 
testing)
Ex-smoker or non 
smoker
n = 133
8.8
(7.9, 9.7)
n = 102
16.6
(14.7, 18.9)
n = 236
20.2
(18.6, 21.9)
n = 102
7.4
(6.7, 8.2)
n = 58
12.3
(10.2, 14.7)
n = 264
13.7
(12.8, 14.7)
Atopy Yes No Yes No Yes No Yes No Yes No Yes No
n = 68
9.9
(8.6,11.5)
n = 62
7.6
(6.7, 8.7)
n = 61
19.8
(16.6, 23.6)
n = 41
12.9
(11.1, 14.9)
n = 141
24.8
(22.2, 27.7)
n = 92
14.9
(13.6, 16.3)
n = 32
9.5
(7.8, 11.5)
n = 69
6.7
(5.9, 7.5)
n = 35
14.0
(10.6, 18.5)
n = 23
10.0
(8.2, 12.2)
n = 149
15.9
(14.4, 17.6)
n 114
11.2
(10.3, 12.2)
Rhinitis Yes No Yes No Yes No Yes No Yes No Yes No
n = 50
9.2
(8.0, 10.7)
n = 83
8.5
(7.4, 9.7)
n = 30
21.0
(16.0, 27.5)
n = 72
15.1
(13.2, 17.4)
n = 97
24.0
(21.2, 27.2)
n = 139
17.9
(16.1, 19.9)
n = 33
9.0
(7.5,10.9)
n = 69
6.8
(6.0, 7.7)
n = 23
13.4
(10.1, 17.8)
n = 35
11.6
(9.0, 14.9)
n = 116
16.1
(14.3, 18.0)
n = 148
12.1
(11.1, 13.1)
Current 
wheeze
Yes No Yes No Yes No Yes No Yes No Yes No
All n = 49
8.4
(6.9, 10.2)
n = 84
9.0
(8.0, 10.0)
n = 35
17.7
(13.4, 23.3)
n = 67
16.1
(14.1, 18.5)
n = 53
28.4
(23.0, 34.9)
n = 183
18.3
(16.9, 19.9)
n = 41
7.6
(6.4, 9.1)
n = 61
7.3
(6.4, 8.4)
n = 18
15.2
(9.4, 24.3)
n = 40
11.1
(9.3, 13.3)
n = 57
16.8
(14.2, 19.8)
n = 207
12.9
(12.0, 13.9)
Taking 
ICS
n = 8
8.0
(4.1, 15.6)
Nil n = 5
24.0
(12.7, 45.5)
n = 1
72.9
n = 17
27.5
(19.6, 38.7)
n = 2
28.5
(NA)
n = 3
8.8
(2.0, 40.0)
n = 4
9.4
(1.9, 45.2)
n = 3
32.4
(9.3, 112.0)
Nil n = 13
17.3
(13.1, 22.8)
n = 3
17.8
(3.3, 96.9)
Not 
taking 
ICS
n = 41
8.5
(6.9, 10.4)
n = 84
9.0
(8.0, 10.0)
n = 30
12.3
(16.8, 22.9)
n = 66
15.8
(13.8, 17.9)
n = 36
28.8
(21.9, 37.8)
n = 181
18.2
(16.8, 19.8)
n = 38
7.5
(6.2, 9.1)
n = 57
7.2
(6.4, 8.2)
n = 15
13.0
(7.7, 22.1)
n = 40
11.1
(9.3, 13.1)
n = 44
16.7
(13.6, 20.5)
n = 204
12.9
(11.9, 13.9)
Current 
asthma
Yes No Yes No Yes No Yes No Yes No Yes No
All n = 21
9.8
(6.9, 14.0)
n = 112
8.6
(7.7, 9.5)
n = 27
21.7
(16.5, 28.5)
n = 75
15.1
(13.2, 17.4)
n = 39
29.7
(23.7, 37.2)
n = 197
18.7
(17.2, 20.4)
n = 18
9.5
(6.5, 13.9)
n = 84
7.0
(6.4,7.8)
n = 10
28.0
(14.7, 53.3)
n = 48
10.3
(8.9, 12.0)
n = 41
15.7
(12.7, 19.5)
n = 223
13.3
(12.4, 14.3)
Taking 
ICS
n = 8
8.0
(4.1, 15.6)
Nil n = 6
28.9
(14.7, 57.0)
Nil n = 18
26.5
(19.1, 36.8)
n = 1
58.3
n = 5
11.0
(3.8, 32.2)
n = 2
5.7
(0.5, 72.1)
n = 3
32.4
(9.3, 112.0)
Nil n = 14
18.3
(13.8, 24.3)
n = 2
12.0
(3.1, 47.4)
Not 
taking 
ICS
n = 13
11.2
(7.1, 17.8)
n = 112
8.6
(7.7, 9.5)
n = 21
20.0
(14.6, 27.4)
n = 75
15.1
(13.2, 17.4)
n = 21
32.7
(23.5, 45.6)
n = 196
18.6
(17.1, 20.2)
n = 13
9.0
(5.8, 14.2)
n = 82
7.1
(6.4, 7.8)
n = 7
26.4
(9.9, 69.9)
n = 48
10.3
(8.9, 12.0)
n = 27
14.6
(10.8, 19.5)
n = 221
13.3
(12.4, 14.4)Respiratory Research 2007, 8:82 http://respiratory-research.com/content/8/1/82
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these factors remained significant after stratifying by sex.
In contrast, current smoking (on the day of testing),
atopy, log IgE, history of rhinitis, and current asthma and
the use of inhaled corticosteroids remained significant in
both males and females.
In the adjusted regression analyses, significant predictors
of FENO were sex, body mass index (BMI), current smok-
ing (on the day of testing), atopy, current asthma, and the
interaction between sex and smoking. Current wheeze
was not a significant factor. This was perhaps because of
the significant confounding relationship between current
smoking (resulting in reduced FENO) and wheeze (p =
0003; model 4; see Additional File 1). Details of all the
models examined are provided in Additional File 1.
After controlling for all of the significant factors affecting
FENO, the sex-related differences in FENO remained sig-
nificant (p < 0.001). The factors which significantly
affected FENO were different for males and females. For
males, current smoking (all), current asthma, and atopy
(any positive SPT ≥ 3 mm over the negative control) were
significant independent predictors of FENO. For females,
while current smoking (all), current asthma, and atopy
Table 3: Factors affecting FENO by linear regression analysis, without controlling for any other factors Magnitude of effect = change 
compared to reference group (females, non-smokers, non-atopics, non-rhinitics, non-wheezers, or non-asthmatics)
All Males Females
Factor Magnitude of 
effect*
Significance Magnitude of 
effect*
Significance Magnitude of 
effect*
Significance
Female Gender 0.7605 <0.0001 --- ---
BMI 1.0015 0.7571 1.0045 0.5600 0.9966 0.5503
Height 1.0013 <0.0001 1.0003 0.5859 1.0007 0.0969
FEV1 1.1315 <0.0001 0.9956 0.9328 1.0229 0.7230
FEV1% predicted 0.9957 0.0166 0.9988 0.6422 0.9981 0.4432
FVC 1.1058 <0.0001 0.9832 0.6963 1.0443 0.4044
Current smoker 
(smoked on day of testing)
0.49600 <0.0001 0.43350 <0.0001 0.54337 <0.0001
Current smoker (within last 12 
months, not smoked on day of 
testing)
0.90579 0.0825 0.82377 0.0091 0.89582 0.1945
Atopy (≥3 mm) 1.6028 <0.0001 1.60363 <0.0001 1.5472 <0.0001
Log IgE 1.3897 <0.0001 1.3971 <0.0001 1.3235 <0.0001
Current rhinitis 1.3126 <0.0001 1.2868 0.0002 1.3670 <0.0001
Current wheeze 1.1009 0.0617 1.0906 0.2349 1.1004 0.1658
Current asthma 1.4132 <0.0001 1.4434 <0.0001 1.3495 0.0003
Using ICS 1.3904 0.0004 1.3780 0.0134 1.3755 0.0130
Table 2: Mean values (with 95% confidence intervals) for FENO, stratified by smoking status and sex
FENO (ppb) Mean 95% C.I. All subjects Males Females
All Study members n = 895
13.4
(12.8, 14.1)
n = 471
15.3
(14.3, 16.3)
n = 424
11.6
(11.0, 12.4)
All current smokers (within last 12 months) n = 395
10.4
(9.7, 11.1)
n = 235
11.6
(10.6, 12.6)
n = 160
8.9
(8.1, 9.8)
Current smokers who smoked on the day of 
FENO testing
n = 235
8.2
(7.6, 8.8)
n = 133
8.8
(7.9, 9.7)
n = 102
7.4
(6.7, 8.2)
Current smokers who did not smoke on day of 
FENO testing
n = 160
14.9
(13.4, 16.6)
n = 102
16.6
(14.7, 18.9)
n = 58
12.3
(10.2, 14.7)
Ex-smokers (greater than 12 months) n = 107
16.0
(14.3, 17.8)
n = 36
21.1
(17.6, 25.3)
n = 71
13.8
(12.2, 15.7)
Never smokers n = 393
16.6
(15.6, 17.7)
n = 200
20.0
(18.3, 22.0)
n = 193
13.6
(12.5, 14.8)Respiratory Research 2007, 8:82 http://respiratory-research.com/content/8/1/82
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(any positive SPT ≥ 3 mm over the negative control) were
significant independent predictors of FENO, those females
who were current smokers and also had asthma had an
additional increase in their FENO (FENO increased by
131%; p = 0.001; Table 4).
Based on these results, the equations for predicting FENO
in our study cohort were:
For males: log FENO = 1.1932 - 0.3496*current smoking
(smoked day of testing) - 0.0940*current smoking (not
smoked day of testing) + 0.16511*atopy +
0.0973*asthma
(R2 = 0.3434)
For females: log FENO = 1.0533 - 0.2407*current smoking
(smoked day of testing) - 0.1160*current smoking (not
smoked on day of testing) + 0.0388*asthma +
0.1355*atopy + 0.0531*current smoking (smoked day of
testing)*asthma + 0.3630*current smoking (not smoked
day of testing)*asthma
(R2 = 0.2760)
where, for the terms current smoking, atopy and asthma,
yes = 1, and no = 0.
Using these equations, the predicted values and ranges
(95% C.I.) for clinically important populations are pre-
sented in Table 5. For comparison, the actual values
obtained from each subgroup of the study population are
also presented.
Discussion
The results of the present study provide further evidence
that sex is a major factor determining exhaled nitric oxide
(FENO) measurements. Without adjusting for other fac-
tors such as atopy, current smoking, and diagnosed
asthma, the mean FENO levels in males were significantly
higher than in females (p = 0.0001). However, even after
appropriate adjustments, this difference persisted. The
magnitude of the difference was approximately 25%. This
is clinically as well as statistically significant [24].
A review of the literature provides somewhat conflicting
data regarding this issue. It is important to take account of
the different methodologies used for FENO measurements
when making comparisons between studies, particularly
with regard to expiratory flow rates. However, within stud-
ies, significant differences between males and females will
still be valid, and the balance of evidence suggests that
sex-related differences in FENO are indeed important. In
early investigations, both Jilma et al. [25] and Tsang et al.
[26] reported sex-related differences in FENO whose mag-
nitude (50% and 53% higher in males compared to
females, respectively) was comparable to the present
Table 4: Adjusted linear regression models with FENO as the dependent variable
Sample Variables Anti-log B-coefficient p-value R-square
All Study Members Intercept 15.9 <0.0001 0.331
Sex 0.69 <0.0001
Current Smoking – smoked on the testing day 0.45 <0.0001
Current Smoking – not smoked on the testing day 0.80 0.0014
Current Asthma 1.26 <0.0001
Atopy 1.41 <0.0001
Sex*Current Smoking – smoked on the testing day 1.32 0.0025
Sex*Current Smoking – not smoked on the testing day 1.10 0.3970
Males Intercept 15.60 <0.0001 0.343
Current Smoking – smoked on the testing day 0.45 <0.0001
Current Smoking – not smoked on the testing day 0.81 0.0021
Current Asthma 1.25 0.0025
Atopy 1.45 <0.0001
Females Intercept 11.31 <0.0001 0.276
Current Smoking – smoked on the testing day 0.57 <0.0001
Current Smoking – not smoked on the testing day 0.77 0.0022
Current Asthma 1.09 0.3460
Atopy 1.37 <0.0001
Current Asthma*Current Smoking – smoked on the testing 
day
1.13 0.4722
Current Asthma*Current Smoking – not smoked on the 
testing day
2.31 <0.0001Respiratory Research 2007, 8:82 http://respiratory-research.com/content/8/1/82
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result. More recently, Olivieri et al. have reported higher
levels in males, with an upper limit of normal of 28.8 ppb,
compared to 21.5 ppb for females [27]. Travers et al. [19]
reported that the mean FENO in males was 23% higher
than in females (95% C.I. 7–43; p = 0.004, n = 191). In
that study, the significance of the difference persisted even
after controlling for height. In the study by Berry et al. a
similar highly significant difference between males and
females was recorded [28]. However, in the largest study
to date to focus on factors affecting FENO, comprising
2,200 subjects, Olin et al. has presented contrasting
results [18]. Although there was a male-female FENO dif-
ference in non-smokers amounting to 19%, this was not
statistically significant in a multiple linear regression anal-
ysis in which adjustments for all other factors were
included [18]. The reasons why the difference failed to
reach statistical significance are unclear.
After adjusting for sex, we found that other anthropomet-
ric factors such as height and lung function were no longer
significant factors affecting FENO. Previously it has been
argued that sex-related differences in FENO result from
differences in the surface area of airway epithelium, the
major source of exhaled NO, and for which height is an
important anthropometric correlate. Thus our results are
perhaps surprising. However, given that plasma levels of
nitrate, a product of NO metabolism, are similarly differ-
ent between the sexes [25,29], it seems unlikely that NO
production in the airways is solely a reflection of differ-
ences in airway size, but rather reflects sex-related differ-
ences in endogenous NO production. This is consistent
with the results of a twin study, which showed that genetic
rather than environmental factors are more important in
determining FENO [30].
Our findings raise the question as to whether guidelines
for the interpretation of FENO should be stratified by sex,
Table 5: Mean values and reference ranges for FENO (with 95% confidence intervals), based on prediction equations for males and 
females. For comparison, the measured values (with 95% confidence intervals) obtained in the Study members are provided
Males Females
Population FENO (ppb) 95% C.I. FENO(ppb) 95% C.I.
Non-smokers, non-atopic, non-asthmatic Predicted 15.6 14.1, 17.2 11.3 10.3, 12.4
Actual 14.7 13.4, 16.1 11.2 10.3, 12.2
Non-smokers, atopic, non-asthmatic Predicted 22.6 18.3, 28.0 15.4 12.6, 18.9
Actual 23.1 20.4, 26.2 15.6 13.9,, 17.4
Non-smokers, non-atopic, asthmatic Predicted 19.5 15.3, 24.9 12.4 9.4, 16.3
Actual 22.5 8.0, 63.8 11.5 7.0, 18.9
Non-smokers, atopic, asthmatic Predicted 28.3 19.8, 40.5 16.9 11.5, 24.9
Actual 30.4 23.9, 38.7 17.2 13.5, 22.1
Smokers (not smoked on the day of 
testing), non-atopic, non-asthmatic
Predicted 12.6 9.9, 18.2 8.7 6.7, 11.3
Actual 13.0 11.0, 15.2 9.6 7.8, 11.7
Smokers (not smoked on the day of 
testing), atopic, non-asthmatic
Predicted 18.2 12.8, 25.5 11.8 8.2, 17.2
Actual 17.6 14.1, 22.0 10.9 8.7, 13.8
Smokers (not smoked on the day of 
testing), non-atopic, asthmatic
Predicted 15.7 10.7, 22.8 21.8 9.2, 51.8
Actual 12.0 7.5, 19.5 16.0 0.3, 743.5
Smokers (not smoked on the day of 
testing), atopic, asthmatic
Predicted 22.8 13.6, 36.9 29.8 11.3, 79.0
Actual 24.0 17.8, 32.4 32.3 14.6, 71.2
Smokers (smoked on the day of testing), 
non-atopic, non-asthmatic
Predicted 7.0 5.6, 8.8 6.5 5.1, 8.2
Actual 7.3 6.4, 8.3 6.5 5.8, 7.3
Smokers (smoked on the day of testing), 
atopic, non-asthmatic
Predicted 10.1 7.2, 14.0 8.9 6.3, 12.5
Actual 10.2 8.8, 11.8 8.9 7.3, 10.9
Smokers (smoked on the day of testing), 
non-atopic, asthmatic
Predicted 8.7 6.0, 12.5 8.0 3.8, 17.0
Actual 8.9 7.3, 10.9 8.1 4.0, 16.4
Smokers (smoked on the day of testing), 
atopic, asthmatic
Predicted 12.6 7.6, 20.3 11.0 4.6, 26.0
Actual 9.3 6.2, 13.8 10.9 6.6, 18.0Respiratory Research 2007, 8:82 http://respiratory-research.com/content/8/1/82
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and that reference ranges for males and females should be
different. In the paper by Olivieri et al. the authors pro-
pose that reference ranges should be stratified for sex [27].
Travers et al. [19] advocate reference ranges based on sex,
smoking status and atopy, but not age or height. We con-
cur with this view, and the reference ranges contained in
Table 5 of the present paper are based on this approach.
In the study by Olin et al. [18], similar to conventional
pulmonary function tests, both age and height but not
sex, were deemed to be significant, although reference val-
ues as such were not provided. All studies concur that
smoking and atopy are important considerations, and
both are included in the reference values given here and
by Travers et al. [19].
In fact, interpreting FENO levels in clinical practice is even
more complex. Reference values which take into account
background characteristics such as sex, atopy and smoking
may indeed be useful in guiding the diagnosis of airways-
related symptoms. In asymptomatic individuals, it is still
possible that increased FENO reflects subclinical airway
inflammation [7,28], but this interpretation is less likely
if appropriate reference values which take factors such as
sex into account have been used in the first place. The
interpretation of FENO levels in the context of ongoing
management of diagnosed asthma is far from clear.
Despite optimal anti-inflammatory treatment, FENO lev-
els may remain resolutely high [31], and it is generally
agreed that normalizing FENO in relation to reference val-
ues for a healthy population is not a desirable therapeutic
aim [8]. This point is perhaps reflected in the results
obtained in the present study, which showed that in non-
smoking, atopic, male asthmatics, who were all clinically
stable, the upper limit of the 95% confidence interval was
38.8 ppb, considerably higher than the levels obtained in
non-smoking, atopic, male, non-asthmatics (28.2 ppb).
One of the weaknesses of our study is that the FENO meas-
urements were obtained in individuals who were all aged
32 years. Thus it was not possible to explore the influence
of age as a factor in the regression analyses or to conclude
whether reference values ought to include it as a factor.
Previous studies have reported that FENO rises with
increasing age in children [15,16,32-34]. In adults, Olin et
al. [18] have reported that an effect of age also occurs:
FENO was shown to increase over the age range 35 to 65
years, with the magnitude of effect similar to that of atopy.
In contrast, in the study by Travers et al. no significant
relationship was noted over a similar age range, but num-
bers were much smaller [19]. In children, it is suggested
that the changes with age are attributable to increasing air-
way NO flux, probably reflecting larger airway surface area
with growth [34]. If at all, any increase in FENO with age
in adults is likely to be due to non-anthropometric factors,
and if the results from Olin et al. are repeatable, this may
be an important consideration.
In summary, our data confirm that differences in FENO
between males and females are of sufficient magnitude
that the interpretation of FENO should be stratified by sex.
This approach should be incorporated into clinical prac-
tice. Other common and easily identified factors such as
current smoking and atopy also require to be taken into
account when interpreting FENO values in adults. Con-
trasting results from a number of studies still leave open
the question as to whether age and height ought to be
included in future reference equations. These outstanding
issues add to the current challenges which still remain in
the application and interpretation of FENO levels in clini-
cal practice, and require further study.
Abbreviations
C.I. confidence interval
FENO fraction of nitric oxide in expired air
FEV1 forced expiratory volume in one second
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NO nitric oxide
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ppb parts per billion
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